Develop molecular genetic diagnostic solutions for life-threatening medical conditions. Specialize primarily in the field of cancer diagnostics. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 57.2× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 10% of them.
No analyst target is on record for this company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are going backwards, not just slowing.
Sales run at $537K a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 16 buys and 4 sells. Management buying with its own money is usually read as a good sign.
A loss of $16.2M against $537K in annual sales. And on top of that, sales fell from the year before.
This stock swings about 2.4 times as much as the market average. Big rallies — and big drops — can both happen fast.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, QUCY sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: QUCY is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: the revenue breakdown, the price history.